Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Entity

Name
nicotinic receptor alpha4beta2
Namespace
MeSH
Namespace Version
20181007
Namespace URL
https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mesh-names.belns

Appears in Networks 1

In-Edges 5

a(CHEBI:varenicline) increases act(a(MESH:"nicotinic receptor alpha4beta2")) View Subject | View Object

Varenicline (Chantix®; Fig. 4) is prescribed as an adjunct medication in smoking cessation therapy and is thought to exert its effects as a partial agonist at α4β2 nAChRs and as a full agonist at α7 nAChRs [211, 212]. PubMed:28391535

a(MESH:"Dihydro-beta-Erythroidine") decreases act(a(MESH:"nicotinic receptor alpha4beta2")) View Subject | View Object

For example, DHβE (at nM concentrations) blocks α4β2 and α3β2 nAChRs but is much less potent at α3β4 and α7 nAChRs expressed in Xenopus oocytes (e.g., [134–137]). PubMed:28391535

Out-Edges 0

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.